Validation of retinoblastoma mouse model based on fluorescence imaging technology
10.3980/j.issn.1672-5123.2025.5.03
- VernacularTitle:基于荧光成像技术验证视网膜母细胞瘤小鼠模型
- Author:
Cailing DAI
1
,
2
,
3
,
4
,
5
;
Wei YANG
1
,
2
,
3
,
4
,
5
;
Limei WANG
1
,
2
,
3
,
4
,
5
;
Jinlong DAI
1
,
2
,
3
,
4
,
5
;
Yuying WEN
1
,
2
,
3
,
4
,
5
;
Jianmin GUO
1
,
2
,
3
,
4
,
5
Author Information
1. Guangzhou Bay Area Institute of Biomedicine
2. Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd.
3. Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research
4. TCM Non-clinic Evaluation Branch of National Engineering Research Center for Modernization of Traditional Chinese Medicine
5. Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou 510990, Guangdong Province, China
- Publication Type:Journal Article
- Keywords:
BALB/c-nu mice;
retinoblastoma;
Y79 cells;
in vivo imaging;
fluorescence imaging technology
- From:
International Eye Science
2025;25(5):706-713
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To provide references for the non-clinical evaluation of therapeutic targets or drugs for retinoblastoma, fluorescently labeled Y79 cells are injected into the vitreous body of BALB/c-nu mice to establish a retinoblastoma model, and the Melphalan treatment group is used as a positive control, which is verified by fluorescence imaging technology.METHODS: BALB/c-nu mice were intravitreous injected with GFP transfected Y79 cells(1.0×107 cell/mL, 3 μL)to establish the model. On the 27th day, the mice were randomly divided into model control group and different doses of Melphalan groups(1, 3, 10 μg/eye groups)according to the fluorescence value of in vivo imaging, with vitreous body single administrated and ocular symptoms observed daily. Slit-lamp examination was performed at 12, 20, 29, 35, 42, 48, 55, 76, and 83 d after modeling. In vivo imaging was performed on 12, 20, 27, 41, 48, 55, 62, 69, 76, and 83 d. At the last treatment, the eyeball, brain and cerebellum tissues were removed for histopathological examination.RESULTS: From the sixth day of modeling, cloud-like substances could be seen in the eyes of the animals, and the cloud-like substances occupied the whole eyeball of the mice in the model control group at the later stage, accompanied by irregular growth of blood vessels. After 27 days of modeling, the fluorescence value was detected in all the animals, and the fluorescence value continued to increase with the extension of modeling time. The fluorescence value of the tumor reached the peak after 69-83 days of modeling. Histological examination showed severe proliferation of intraocular tumor cells in the model control group, and tumor cells were observed in the brain of 1 model animal. In the 10 μg/eye Melphalan group, the fluorescence value was significantly decreased at 17 d after administration. The fluorescence value of the 3 μg/eye Melphalan group was significantly inhibited at 59 d after administration. No tumor cells were found in the brain tissue of animals in all Melphalan groups.CONCLUSION: After vitreous injection of Y79/pCDH-LUC-copGFP cells in BALB/c-nu mice, significant ocular lesions and proliferation of tumor cells were observed in the eyes. Meanwhile, Melphalan intervention significantly inhibited tumor cells in a dose-dependent manner, indicating that the mouse model of retinoblastoma was successfully constructed.
